Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model

International Journal of Cancer

Volumn 125, Issue 10, 2009, Pages 2450-2455

  Fayad, Walid ^a   Brnjic, Slavica ^a   Berglind, Daniel ^a   Blixt, Susanna ^a   Shoshan, Maria C ^a   Berndtsson, Maria ^a   Olofsson, Maria Hägg ^a   Linder, Stig ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Cisplatin; p21Cip1; p27Kip1; Senescence

Indexed keywords

BETA GALACTOSIDASE; CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MULTICELLULAR SPHEROID; PRIORITY JOURNAL; SENESCENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; COLONIC NEOPLASMS; DNA DAMAGE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, SCID; SPHEROIDS, CELLULAR; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349861908     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24627     Document Type: Article

References (41)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-584
2. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001;67:93-130. (Pubitemid 33804642)
3. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-2498
4. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320 (Pubitemid 41130944)
5. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990;2:275-280 (Pubitemid 20290110)
6. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279
7. Mandic A, Viktorsson K, Strandberg L, Heiden T, Hansson J, Linder S, Shoshan MC. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol 2002;22:3003-3013 (Pubitemid 34437459)
8. Sanchez-Perez I, Murguia JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998;16:533-540 (Pubitemid 28062081)
9. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003;278:9100-9106 (Pubitemid 36800390)
10. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007;120:175-180 (Pubitemid 44901933)
11. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, Modjtahedi N, Harel-Bellan A, et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008;27:4221-4232
12. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-237 (Pubitemid 40314954)
13. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle 2008;7:1353-1359
14. Clarke PA, Pestell KE, Di Stefano F, Workman P, Walton MI. Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo. Br J Cancer 2004;91:1614-1623 (Pubitemid 39486371)
15. Tannock IF, Lee C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anticancer drugs. Br J Cancer 2001;84:100-105 (Pubitemid 32102512)
16. Guerriero JL, Ditsworth D, Fan Y, Zhao F, Crawford HC, Zong W-X. Chemotherapy induces tumor clearance independent of apoptosis. Cancer Res 2008;68:9595-9600
17. Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 2000;82:436-440 (Pubitemid 30045394)
18. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 1979;5:1225-1230
19. Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol 2004;24:6837-6849 (Pubitemid 38944361)
20. Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 1994;13:121-138
21. Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997;57:2388-2393 (Pubitemid 27255896)
22. Herrmann R, Fayad W, Schwarz S, Berndtsson M, Linder S. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids. J Biomol Screen 2008;13:1-8.
23. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363-9367
24. Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedrac R, Wilkinson RW, Mundt KE, Busk M, et al. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. Cancer Biomark 2009;5:117-125
25. Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 2003;83:173-180 (Pubitemid 36734131)
26. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322
27. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-1210 (Pubitemid 26375403)
28. Mellor HR, Ferguson DJ, Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer 2005;93:302-309 (Pubitemid 43080032)
29. Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993;53:2212-2216
30. He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer 2006;95:1514-1524 (Pubitemid 44863354)
31. Horan PK, Slezak SE. Stable cell membrane labelling. Nature 1989;340:167-168
32. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-1756 (Pubitemid 38428698)
33. Micha D, Cummings J, Shoemaker A, Elmore S, Foster K, Greaves M, Ward T, Rosenberg S, Dive C, Simpson K. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin Cancer Res 2008; 14:7304-7310
34. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-884
35. Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res 1975;35:2619-2630
36. Driessens G, Harsan L, Robaye B, Waroquier D, Browaeys P, Giannakopoulos X, Velu T, Bruyns C. Micronuclei to detect in vivo chemotherapy damage in a p53 mutated solid tumour. Br J Cancer 2003;89:727-729 (Pubitemid 37076181)
37. Shimada M, Kigawa J, Kanamori Y, Itamochi H, Takahashi M, Kamazawa S, Sato S, Terakawa N. Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts. Eur J Cancer 2000;36:1869-1875 (Pubitemid 30639508)
38. Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH, Park BW, Yun CO. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 2006;17:379-390
39. Jiang QQ, Fan LY, Yang GL, Guo WH, Hou WL, Chen LJ, Wei YQ. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer 2008;8:242.
40. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004;214:1-9. (Pubitemid 39141193)
41. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002;8:2766-2774 (Pubitemid 35025718)